| Document |
Document Title |
|
WO/2023/096987A1 |
The present disclosure relates to bifunctional compounds, which find utility as modulators of SMARCA2 or BRM (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a ligand...
|
|
WO/2023/094827A1 |
Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof wherein X1, R3, R4, a, b, p, q, r, L, and Ring A are as defined herein. The compounds are antagonists of the resistant (R-type) voltage-gated calciu...
|
|
WO/2023/093728A1 |
The present disclosure relates to a proteolysis-targeting chimera (PROTAC) molecule, further relates to a BRM selective degradation agent compound, and specifically provides a compound of formula (I) or a pharmaceutically acceptable salt...
|
|
WO/2023/096304A1 |
The present invention relates to an isoxazole derivative or a pharmaceutically acceptable salt thereof and a composition for preventing or treating CSF-1R related diseases comprising the derivative as an active ingredient. The isoxazole ...
|
|
WO/2023/097007A1 |
The present disclosure features compounds and related compositions that, inter alia, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.
|
|
WO/2023/097020A1 |
Disclosed are Hematopoietic Progenitor Kinase 1 (HPK1) degradation / disruption compounds including a HPK1 ligand, a degradation / disruption tag and a linker, and methods for use of such compounds in the treatment of HPK1-mediated disea...
|
|
WO/2023/088229A1 |
Provided in the present invention is a method for synthesizing rivaroxaban. The method comprises: reacting an intermediate I and an intermediate II in an organic solvent in the presence of an alkali to obtain rivaroxaban, wherein the syn...
|
|
WO/2023/091606A1 |
Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, amon...
|
|
WO/2023/091707A1 |
The present disclosure provides inhibitors of the Janus family of tyrosine kinases (JAK). Also disclosed are methods to modulate the activity of JAK and methods of treatment of disorders mediated by JAK.
|
|
WO/2023/088420A1 |
The present disclose includes, among other things, compounds that treat or lessen the severity of cancer, pharmaceutical compositions and methods of making and using the same.
|
|
WO/2023/090859A1 |
The present invention relates to: a novel method for preparing an isoxazole derivative, which is useful as a farnesoid X receptor (FXR, NR1H4) agonist; a novel intermediate used in the preparation method; and a method for preparing the p...
|
|
WO/2023/088233A1 |
Described herein are KAT6A inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of a disease or disorder associated with KAT6A.
|
|
WO/2023/088477A1 |
Disclosed in the present invention are a Bruton's tyrosine kinase degrading agent, which has a structure represented by general formula I; or a stereoisomer, a mixture of stereoisomers, or a pharmaceutically acceptable salt and a prodrug...
|
|
WO/2023/091554A1 |
The invention provides new heteroaromatic compounds having the general formula (I'), or a solvate or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, Y1, Y2, Y3, and n are as defined herein, compositions includ...
|
|
WO/2023/090858A1 |
The present invention relates to: a novel method for preparing an isoxazole derivative that is useful as an agonist for a farnesoid X receptor (FXR, NR1H4) and an intermediate for preparing the agonist; and a method for preparing an inte...
|
|
WO/2023/090822A1 |
The present invention provides a cannabichromenic acid derivative, a preparation method therefor, and a composition comprising same for improving cognitive function. A novel cannabichromenic acid derivative of the present invention has b...
|
|
WO/2023/091565A1 |
The current invention relates to nuclear receptor-binding SET domain-containing 2 (NSD2)- targeted protein degradation reagents and pharmaceutical compositions thereof and their utility as anti- cancer agents.
|
|
WO/2023/090829A1 |
The present invention relates to an anticancer pharmaceutical composition containing a bicyclic low-molecular-weight derivative as an active ingredient and a method for preparing same, and the composition containing the bicyclic derivati...
|
|
WO/2023/092107A1 |
The present disclosure provides a compound represented by structural formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.
|
|
WO/2023/091456A1 |
The present invention refers to compounds of formula (I), as HTT modulators for the treatment of Huntington's disease. An exemplary compound is e.g. example 1: (R)-5-(3- (cyclopropylamino)pyrrolidin-l-yl)-N-(2-methyl-6-(oxazol-5-y
lmetho...
|
|
WO/2023/092088A1 |
The present disclosure provides a compound represented by structural formula (I): (I), or a pharmaceutically acceptable salt thereof useful for treating a cancer.
|
|
WO/2023/088441A1 |
Disclosed are a class of KIF18A inhibitors, and specifically disclosed are a compound represented by general formula (1) and a preparation method therefor, and a use of a compound represented by general formula (1) and an isomer, crystal...
|
|
WO/2023/088620A1 |
The present invention relates to a phosphine of the formula (1), wherein - Q is SiR3R4, GeR3R4, SnR3R4, AsR3 or Se; - m is 0, 1, 2 or 3; n is 0, 1, 2 or 3; under the proviso that m + n ≥ 1; - the groups R independently of each other re...
|
|
WO/2023/084158A1 |
The present invention relates to a compound of formula (I) wherein A, B, R1, R2, R3, R4 and R5 are as defined in claim 1, or pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as cytochr...
|
|
WO/2023/086539A2 |
The disclosure is directed to compounds, and pharmaceutically acceptable salts thereof, that inhibit branched-chain amino acid aminotransferase 2 (BCAT2), pharmaceutical compositions comprising those compounds, and methods of using those...
|
|
WO/2023/087027A1 |
Described herein are compounds that are ULK1/2 inhibitors and their use in the treatment of disorders such as cancers.
|
|
WO/2023/083269A1 |
Disclosed are an aromatic heterocyclic compound and an application thereof. The present invention provides an aromatic heterocyclic compound as represented by formula I, and the compound has good LSD1 enzyme inhibitory activity, and can ...
|
|
WO/2023/084449A1 |
The disclosure relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof wherein A and B are as described herein, as well as compositions and methods of using such compounds.
|
|
WO/2023/082145A1 |
Provides compound of formula A, use in intermediates and bulk medicines thereof, and synthesis method thereof. The method avoids cumbersome separation and purification steps, reduces costs, improves reaction yield, avoids the use of POCl...
|
|
WO/2023/085415A1 |
Provided is a compound represented by formula (1), or a pharmaceutically acceptable salt thereof. [In the formula, R1 denotes a hydrogen atom, an alkyl group, an alkoxy group or an alkoxyalkyl group, each R2 moiety independently denotes ...
|
|
WO/2023/085785A1 |
The present invention relates to an isoindolinone derivative compound having a glutarimide mother nucleus, and the application thereof and, more specifically, to an isoindolinone derivative compound having a glutarimide mother nucleus ha...
|
|
WO/2023/083343A1 |
Among other things, the present disclosure provides technologies, e.g., compounds, compositions, methods, use for preventing or treating various conditions, disorders or diseases. In some embodiments, a condition, disorder or disease is ...
|
|
WO/2023/083847A1 |
Isoxazolidines as RIPK1 inhibitors and use thereof The present disclosure relates to isoxazolidines and their use as receptor-interacting protein kinase 1 inhibitors, for example in the treatment of diseases and disorders mediated by RIP...
|
|
WO/2023/079294A1 |
The invention relates to compounds of formula (Ia) and to their use in treating or preventing an inflammatory disease, a disease associated with an undesirable immune response, cancer, obesity, a diabetic disease or a blood disorder: whe...
|
|
WO/2023/081312A1 |
The present disclosure provides compounds or salts of Formula (I) which modulate Beclin-l/Bcl-2 protein- protein interactions. These interactions induce autophagy and are useful for treating a variety of indications, including cancer, in...
|
|
WO/2023/079128A1 |
The invention provides a process for manufacturing an aniline (2), wherein PG denotes hydrogen or an amino protective group, that is suitable for large-scale manufacturing of said aniline (2).
|
|
WO/2023/081209A1 |
Compounds of Formula (I) and pharmaceutically active salts thereof are provided, where the variables in Formula (I) are described herein. Such compounds and salts are PI3K inhibitors that are useful for treating conditions characterized ...
|
|
WO/2023/078337A1 |
The disclosure provides for compounds and methods for modulating or inhibiting CDK8/19. In one aspect, described herein are compounds of Formula (A'), (A), (A-I), (A-II), (II), (II-I), (II-II), (III), (B), (IV), (V), (VI), and (VII), and...
|
|
WO/2023/080765A1 |
The present invention pertains to an oxadiazole derivative and a composition containing same for preventing or treating NADPH oxidase (NOX)-related diseases. The present invention can be used to treat NADPH oxidase (NOX)-related diseases...
|
|
WO/2023/079291A1 |
This invention relates to novel compounds and pharmaceutical compositions comprising the novel compounds of formula (I). More specifically, the invention relates to compounds useful as inhibitors of discoidin domain receptor 1 (DDR1) and...
|
|
WO/2023/078207A1 |
Disclosed are a 6-position-substituted indolinone derivative, a preparation method therefor, and a medical use thereof. The present invention belongs to the field of medicinal chemistry; the 6-position-substituted indolinone derivative o...
|
|
WO/2023/078451A1 |
The present invention relates to a compound used as a CDK7 kinase inhibitor and a use thereof. Specifically, the compound of the present invention has the structure shown in formula I, the definitions of the groups and substituents being...
|
|
WO/2023/078461A1 |
A heterocyclic compound as shown in formula I, a tautomer, stereoisomer, solvate, pharmaceutically acceptable salt or prodrug thereof, a preparation method therefor, and the use thereof. The heterocyclic compound has a better 15-PGDH inh...
|
|
WO/2023/077726A1 |
The present invention provides an organic compound, a light extraction layer material, and an organic electronic device. The structure of the organic compound is represented as general formula (1). The organic compound can be used as the...
|
|
WO/2023/079556A1 |
The present invention provides compounds and pharmaceutical compositions comprising thereof. Further, methods for increasing or prolonging the therapeutic efficacy of a chemotherapeutic agent in a subject in need thereof, and methods for...
|
|
WO/2023/076237A1 |
The present application provides compounds that may be used as a glucagon-like peptide-1 receptors (GLP-1R) agonist, or pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions containing such compounds, o...
|
|
WO/2023/070700A1 |
Provided are a compound using fluorene as a core, and a preparation method therefor and the use thereof. By means of changing the types of a donor and an acceptor and bonding positions, an electroluminescent device having a series of blu...
|
|
WO/2023/073082A1 |
The present invention relates to compounds of Formula (I), their synthesis and use as CCR6 receptor modulators for the prevention or treatment of e.g. inflammatory/autoimmune diseases/disorders and cancer.
|
|
WO/2023/077070A1 |
The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such ...
|
|
WO/2023/072026A1 |
Provided herein are compounds of Formula (I), compositions comprising the same, and methods of using the same, including use in treating various diseases and conditions, e.g., those caused by axonal degeneration.
|
